FDA approves expansion of Alpha Tau’s glioblastoma trial to 20 patients
DRTS•The FDA cleared Alpha Tau Medical to expand its Alpha DaRT REGAIN trial in recurrent glioblastoma from 10 to 20 patients.
1. Trial expansion
The expanded protocol adds progression-free survival and quality-of-life assessments, along with an additional interim analysis.
